Emergent BioSolutions Inc. (EBS) Stock Analysis
Free AI-powered analysis and research for Emergent BioSolutions Inc. stock
Sector: Healthcare
Full EBS report
Emergent BioSolutions Inc. (EBS) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze EBS Now βπ° Latest Update
Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ...
Thu, November 5, 2026 at 7:01 AM UTC 2 min read
Emergent BioSolutions Inc (EBS) reported Q3 2026 revenue of $110 million, significantly down from $231 million in Q3 2025, primarily due to revenue timing and competitive pressures in the naloxone market. The company raised its FY2026 adjusted gross margin guidance to 45%-47% and expects approximately $40 million in annualized savings from restructuring efforts. Despite challenges, year-to-date revenue remains in line with expectations at $500 million, with adjusted EBITDA at negative $5 million for the quarter.